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Background/aim: The aim of this study is to identify the copeptin levels in patients presenting with carbon monoxide (CO) poisoning
to the emergency department and to investigate its correlation with the neurological effects.
Materials and methods: The study group consisted of patients presenting with CO poisoning and carboxyhemoglobin levels >10%.
Blood samples for copeptin levels were obtained twice, first at presentation then at the fourth hour of observation. The data were
analyzed using SPSS 16 for Windows.
Results: The median copeptin levels of the patient group were identified as 0.63 (0.39–1.06) ng/mL at hour 0 and 0.41 (0.31–0.49) at
hour 4. The copeptin levels of the control group were 0.34 (0.25–0.42) ng/mL and were significantly lower than those of the patient
group (P < 0.000). According to our results, 0.345 ng/mL for plasma copeptin level as the best cut-off level may be used with sensitivity
of 94.0% and specificity of 60%. The copeptin levels at hour 0 were statistically significantly higher in the neurologically affected patients
than those not affected (P < 0.001).
Conclusion: In this study it was shown that blood copeptin levels increase in patients presenting to the emergency department with
CO poisoning.
Key words: Carbon monoxide poisoning, copeptin, neuromarker

1. Introduction
Carbon monoxide (CO) poisoning is a health problem that
frequently occurs in Turkey and worldwide. In Turkey, it
accounts for 30% of the poisoning cases that end with
death (1).
This colorless, odorless, tasteless, and nonirritating
gas is produced as a result of the incomplete burning of
organic matter that can easily be absorbed by the lungs.
CO poisoning can cause cerebral, cardiac, and general
ischemia. The poisoning can be diagnosed according to
the blood carboxyhemoglobin (COHb) levels. There is a
weak correlation between blood COHb levels and organ
damage. Poisonings higher than 60% end with death
and at lower levels clinical findings range from mild to
severe. It is not always possible to identify this using the
COHb level (2). Biochemical markers other than COHb
are being studied to identify the clinical outcomes of
* Correspondence: emineakinci@yahoo.com

this poisoning with neurotoxic and cardiotoxic effects in
particular (3).
Copeptin is excreted from the posterior hypophysis
simultaneously with vasopressin and reflects the amount
of vasopressin in circulation. Copeptin is more stable than
vasopressin in plasma and serum. Studies conducted have
reported that copeptin and vasopressin levels float parallel
to each other both in healthy individuals and in the
critically ill patient population. Recently copeptin has been
investigated as a diagnostic and prognostic factor in many
diseases like pneumonia, heart failure, and hemorrhagic
and septic shock and it has been identified that its levels
rise in correlation with the severity of the disease (4–7).
The aim of this study is to identify the copeptin levels
in patients presenting to the emergency department with
CO poisoning and to investigate its correlation with
neurological damage.
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2. Materials and methods
This study is a prospective controlled study conducted
in the emergency department of the Ankara Keçiören
Training and Research Hospital after obtaining permission
from the local ethics board. Patients presenting to the
emergency department with a clinical picture of CO
poisoning between November 2012 and April 2013 with
COHb levels higher than 10% that agreed to participate
in the study were included in the study. The control
group was selected from healthy volunteers of the same
age group consistent with the study population. Patients
under 18 years of age, kidney failure cases, patients using
corticosteroids, and pregnant patients were excluded from
the study. The demographic characteristics, CO source,
time to arrival to the emergency department, presentation
complaints, and systemic and neurological findings were
recorded on the form prepared. The patients with a history
of syncope, convulsion, Glasgow coma score (GCS)
of <15 at presentation, and neurological deficits were
regarded as neurologically affected. Patients were treated
with normobaric (NBOT) or hyperbaric (HBOT) oxygen
therapy accordingly. The HBOT indications were syncope,
loss of consciousness, seizures, coma, blood COHb
levels >25%, focal neurological deficits, and findings
of acute myocardial ischemia. The other patients were
administered 100% NBOT with a reservoir mask in the
emergency department. Blood samples were taken twice,
at presentation and the fourth hour of observation.
2.1. Blood specimen measurement
The blood samples for copeptin levels were taken at the
time when patients were first admitted to the emergency
department and 4 h after the patient’s initial admission.
The blood samples for copeptin levels were taken into
tubes used for biochemistry samples and were centrifuged.
Centrifuged blood samples were kept at –80 °C until all
blood samples were obtained. The blood samples were
analyzed using the manual ELISA immunoassay method
with copeptin kits.
2.2. Statistical methods
The analysis of the data was done using SPSS 16 for
Windows. The consistency of truncated and continuous
variables with normal distribution was investigated using
the Kolmogorov–Smirnov test. Descriptive statistics
were expressed as mean ± standard deviation or median
(minimum–maximum) for truncated and continuous
variables and as the number of cases and (%) for categorical
variables.
The presence of statistically significant changes in the
mean values of the patient and control groups was evaluated
using the independent double sample t-test and median
values of data not consistent with normal distribution
were evaluated using the Mann–Whitney U test. P <
0.05 was set for statistically significant results. Receiver
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operating characteristic (ROC) curves were conﬁgured
to establish the cut-off point of the plasma copeptin level
with the calculated area under the curve (AUC) and 95%
confidence interval. P < 0.05 was considered significant.
3. Results
The study was conducted with 51 patients exposed to CO
who met the inclusion criteria and 48 healthy volunteers
with a similar age and sex distribution. Most of the
presentations occurred between 0000 and 0400 hours at a
rate of 27.5% and most of the poisonings were caused by
gas (39.2%). The mean COHb levels were 30.11 ± 6.71%
at presentation and 7.46 ± 3.22% at hour 4. Eight patients
received HBOT and 43 received NBOT (Table 1).
The mean copeptin levels of the patient and control
groups are shown in Table 2. The drop in the copeptin
levels that occurred at hour 4 after observation and
treatment was statistically significant when compared to
the baseline levels (hour 0) (P < 0.000) (Table 2).
The validity of the tests was evaluated by an analysis
of ROC curves. The ROC curve identiﬁed that a plasma
copeptin level of >0.345 ng/mL predicted patients with
94% sensitivity and 60% speciﬁcity, while the positive
predictive value was 70% and the negative predictive value
was 90% (AUC: 0.856; 95% confidence interval: 0.785–
0.927) (Figure).
While the copeptin levels at hour 0 of patients
neurologically affected after carbon monoxide poisoning
(syncope, convulsions, etc.) were significantly higher than
those of patients not neurologically affected, there was no
statistically significant difference in the levels of copeptin
at hour 4 between the groups (respectively P <0.000 and P
= 0.057) (Table 3).
4. Discussion
The toxicity caused by CO inhalation is a condition that
might cause permanent damage to tissues with high oxygen
consumption like the brain or heart and may be fatal as it
causes generalized and cerebral hypoxia. Many acute or
late neurological/psychiatric disorders can develop after
CO poisoning. In the acute period, early symptoms like
headaches, nausea, and loss of concentration may develop.
As the duration of exposure increases syncope, confusion,
epileptic seizures, and coma may occur. Patients may
also present with symptoms of acute stroke (8). In the
late period of CO poisoning ‘delayed neuropsychiatric
syndrome’ may develop weeks after the findings of acute
intoxication disappear. It is predicted that this syndrome
develops in 10%–30% of patients (8). Many biomarkers
have been investigated to predict the neurological damage
occurring in the acute and late phases of CO poisoning.
Yardan et al., who investigated serum S100B and neuronspecific enolase (NSE), reported that these markers were
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Table 1. The demographic characteristics of the patients.
Age, years
Mean ± SD (minimum–maximum)

41.41 ± 17.69 (18–83)

Sex, n (%)
Male
Female

23 (45.1%)
28 (54.9%)

CO source, %
Gas
Stove
Gas water heater

39.2%
33.3%
27.5%

Time to arrival to the emergency department, minutes
Mean ± SD (minimum–maximum)

23.14 ± 22.9 (10–120)

COHb level, %
Median (minimum–maximum)

29.8 (17.9–53.7)

Presentation symptoms, %
Headache
Nausea
Dizziness
Vomiting
Syncope
Confusion

80.4%
62.7%
52.9%
27.5%
9.8%
5.9%

GCS score
Mean ± SD (minimum–maximum)

14.98 ± 0.14 (14–15)

HBOT, n (%)
NBOT, n (%)

8 (15.7%)
43 (84.3%)

COHb: Carboxyhemoglobin, CO: carbon monoxide, GCS: Glasgow coma score, NBOT: normobaric
oxygen therapy, HBOT: hyperbaric oxygen therapy.
Table 2. The copeptin levels of the patient and control groups at presentation (hour 0) and the copeptin levels
of the patient group at hour 4.
Carbon monoxide group

Control group

P

Hour 0 copeptin, ng/mL
Median (IQR 25–75)

0.63 (0.39–1.06)

0.34 (0.25–0.42)

<0.001

Hour 4 copeptin, ng/mL
Median (IQR 25–75)

0.41 (0.31–0.9)

P

<0.001

useful in evaluating the hypoxic brain damage in CO
poisoning, especially in unconscious patients (9). Brvar
et al. identified higher S100B levels in patients with GCS
of ≤8 at presentation to the emergency department (10).
Akdemir et al. identified higher S100B and NSE levels in
all patients, conscious or unconscious, and higher glial
fibrillary acidic protein (GFAP) levels only in unconscious
patients in their study that evaluated S100B, NSE, and
GFAP levels. The authors proposed that these three markers
are useful in evaluating the severity of CO poisoning (11).

Copeptin is a stress hormone synthesized together
with vasopressin and it is a new diagnostic biomarker for
patients presenting with acute diseases (12). In this study
it was found that the copeptin levels were significantly
higher in CO-poisoned patients than the control group. In
addition, the blood copeptin levels after treatment at hour
4 were significantly lower than the levels at presentation.
According to our results, 0.345 ng/mL for plasma
copeptin level as the best cut-off level may be used with
sensitivity of 94.0% and specificity of 60%. However, our
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Figure. Graph showing the predictive signiﬁcance of hour 0 plasma copeptin
level for carbon monoxide (CO) poisoning. Receiver operating characteristic
(ROC) curve was constructed based on the sensitivity and speciﬁcity of the plasma
copeptin concentration for CO poisoning. The area under the curve was calculated
based on the ROC curve and expressed as a 95% conﬁdence interval. For the
accuracy of the test, a value of 1.0 represents 100% sensitivity and specificity, and a
value of 0.5 indicates no discriminatory power.
Table 3. The copeptin levels of patients with and without neurological findings.
Patients with neurological findings
Median (IQR 25–75)

Patients without neurological findings
Median (IQR 25–75)

P

Hour 0 copeptin, ng/mL
Median (IQR 25–75)

1.48 (1.32–4.66)

0.56 (0.37–0.81)

<0.001

Hour 4 copeptin, ng/mL
Median (IQR 25–75)

0.49 (0.35–0.83)

0.41 (0.30–0.47)

0.057

cut-off level and control median values are very close;
therefore, a higher level of copeptin may be considered in
clinical practice.
Copeptin has been used as a diagnostic and prognostic
neuromarker in many studies in the past years (13,14). It has
been shown that copeptin is a reliable marker for predicting
long-term outcomes, particularly in ischemic stroke. It
has been shown that the prognostic value of copeptin in
predicting the 1-year mortality and morbidity in stroke
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patients increases when the National Institutes of Health
Stroke Scale is added. Although copeptin is not a specific
marker, unlike other neuromarkers it directly bypasses
the blood–brain barrier and is excreted into systemic
circulation and thus it reflects the intracerebral condition
better (14). A significant correlation has been shown
between copeptin levels and prognosis and the GCS at
presentation, not only in patients presenting with ischemic
stroke but also for acute intracerebral hemorrhages (15).
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Although the number of patients affected neurologically
is low in the study that we are presenting, the copeptin
levels of the neurologically affected patients at hour 0
were statistically significantly higher than those of patients
not neurologically affected. However, we did not find a
statistically significant difference in the level of copeptin at
hour 4 between these groups. We think that this resulted
from the significantly decreased copeptin levels in all
patients after treatment. To our knowledge, there is only
one related study on CO poisoning in the literature (16).
In that study, conducted by Pang et al., the severity of the
poisoning and the copeptin levels were evaluated in COpoisoned patients. They identified higher copeptin levels
in patients with lower GCS. In the same study, it was
found that the copeptin levels were higher in patients that
developed delayed neurological sequelae. As a result of
that study, it was stated that copeptin can be used in CO
poisoning, particularly in the diagnosis and observation of
cerebral damage (16).

In the study that we conducted it was observed that
the copeptin levels at hour 4 had significantly dropped
in patients that had received O2 therapy. Thus, we think
that copeptin levels may also be used in evaluating the
efficacy of oxygen therapy in patients presenting with CO
poisoning.
The present study had several limitations. Our study
is a single-center study and included a small number of
cases. In addition, the study did not measure other plasma
neuromarkers such as NSE levels, so it did not evaluate the
relationship between those levels and copeptin levels in
the patients with neurological findings in CO poisonings.
In conclusion, it was observed that blood copeptin
levels rise in patients presenting to the emergency
department with CO poisoning. We think that this stress
hormone can be used as a diagnostic and monitoring tool
in CO poisonings, particularly in detecting neurological
damage. Our study was conducted with a small patient
group and studies with larger patient groups are required.
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